Cornea/External Disease News

The FDA approved Tyrvaya nasal spray for the treatment of signs and symptoms of dry eye disease, according to a press release from Oyster Point Pharma.

Doctor: “We need to start doing InflammaDry on our dry eye disease patients again. I haven’t seen an ID in weeks. When did we quit using it?”

Patients with keratoconus and relatively regular astigmatism can benefit from toric IOLs, provided that keratoconus-specific formulae are used for lens power calculation, according to a speaker.

At the ESCRS meeting, Emilio Torres, MD, speaks about his studies on the role of Bowman’s layer in the biomechanics of the cornea.

Transepithelial corneal cross-linking with supplemental oxygen achieved comparable corneal stromal demarcation line depth to that of conventional epi-off CXL and had a similar safety profile in a study.

In this video from the ESCRS meeting, Farhad Hafezi, MD, PhD, speaks about epithelial-on corneal cross-linking at the slit lamp.

The FDA has approved a supplemental new drug application for Dextenza, adding ocular itching associated with allergic conjunctivitis to the drug’s current indications, according to a press release from Ocular Therapeutix.

In this video from the ESCRS meeting, Marcus Ang, MBBS, PhD, speaks about his pioneering work with OCT angiography for the cornea and anterior segment.

An anterior segment OCT study showed that the corneas of children who frequently rub their eyes have abnormal epithelial thickness distribution, with thinning in the inferotemporal area on the dominant-hand side.

The first three installments of our blog on the complex cornea provided an overview of considerations in these patients when they present for cataract surgery.